TNON News & Events

Tenon Medical announced it has received U.S. Food and Drug Administration, FDA, 510(k) clearance for its Catamaran SI Joint Fusion System. The updated clearance incorporates various instrument upgrades, as well as the reclassification of certain instruments from disposable to reusable status. These enhancements are designed to further improve the performance of the Catamaran System while delivering meaningful economic benefits to the Company by eliminating ongoing per-procedure costs previously associated with disposable instrumentation.

Tenon Medical has priced a public offering of securities as described below for aggregate gross proceeds to the Company of approximately $4.2M, before deducting placement agent fees and other estimated offering expenses payable by the Company. The offering consists of up to 11,052,631 shares of common stock, par value $0.001 per share, together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock, at a combined public offering price of $0.38 per share of common stock and accompanying Common Warrants. WallachBeth Capital is acting as sole placement agent in connection with the offering.